Abstract

A new chewable tablet containing cimetidine 200 mg and alginic acid 500 mg, at a dosage of one tablet four times daily, was compared in a 12 week randomised study with the standard dosage of cimetidine (400 mg four times daily) in the management of oesophageal reflux disease. The dose of cimetidine continued unchanged throughout the study but the dose of the combination drugs could be increased after six weeks to two tablets four times a day if response was unsatisfactory. A total of 312 patients had data suitable for analysis. Sixty three per cent of those on the combination tablet completed the study without increasing their dose - that is taking cimetidine equivalent to half the standard dosage used in the control group. The improvement in heartburn symptoms was significantly greater in the combination group than in the group taking full dose cimetidine. There were no significant differences between the treatment groups in healing and improvement of the appearances of oesophagitis after 12 weeks, and healing rates were as expected from previous studies. The addition of alginic acid to cimetidine in this fixed combination tablet is an improvement in symptomatic treatment of oesophageal reflux disease.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.